GSK (GSK) and Pfizer (PFE) announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has recommended the expanded use of their respiratory syncytial virus (RSV) vaccines.The ACIP has now recommended the use of GSK’s RSV vaccine, Arexvy, and PFE’s RSV vaccine, Abrysvo, in adults aged 50-59 who are at high risk of severe RSV disease. Individuals with underlying medical conditions like obesity, cardiovascular disease, diabetes, chronic obstru ...

Core Viewpoint - GSK plc is facing a class action lawsuit from investors due to alleged misleading statements and failure to disclose critical information regarding the carcinogenic risks associated with its heartburn medication, Zantac, during the specified class period [1][4]. Company Overview - GSK and its subsidiaries are involved in the research, development, and manufacturing of vaccines, specialty, and general medicines aimed at preventing and treating diseases [3]. Legal Allegations - The lawsuit claims that GSK was aware of the carcinogenic compound N-nitrosodimethylamine (NDMA) produced by Zantac's active ingredient, ranitidine, since 1982 but failed to disclose this information [3][6]. - GSK's Zantac generated billions in revenue over two decades, and the company is accused of making false or misleading statements throughout the class period [3][4]. Financial Impact - A Deutsche Bank report on August 10, 2022, estimated GSK's potential liability exposure between $5 billion and $10 billion, leading to a more than 10% drop in GSK ADRs [4]. - Following GSK's acknowledgment of potential liability exposure between $1 billion and $10 billion on August 15, 2022, GSK ADRs declined an additional 3% [5].

NEW YORK, April 7, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of GSK plc (NYSE: GSK).Shareholders who purchased shares of GSK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/gsk-loss-submission-form/?id=140967&from=4CLASS PERIOD: February 5, 2020 to August 14, 2022ALLEGATION ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In GSK To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in GSK between February 5, 2020 and August 14, 2022 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, April 06, 2025 (GLOBE NEWSWIR ...

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, April 03, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises GSK plc ("GSK" or the "Company") (NYSE: GSK) investors of a class action representing investors that bought securities between February 5, 2020 and August 14, 2022, inclusive (the "Class Period"). GSK investors have until April 7, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310 ...

Researchers investigated whether the shingles (herpes zoster) vaccine can help prevent dementia. Previous studies suggest that certain herpes viruses may contribute to dementia, and vaccines might have immune benefits.The new research, published on Wednesday, Nature analyzed data from 282,541 older adults in Wales and found that people who received the original shingles live virus vaccine were 20% less likely to develop dementia than non-vaccinated participants.Also Read: Trump Administration Weighs Deep Cu ...

NEW YORK, April 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of GSK plc (NYSE: GSK).Shareholders who purchased shares of GSK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/gsk-loss-submission-form/?id=140384&from=4CLASS PERIOD: February 5, 2020 to August 14, 2022ALLEGATION ...

NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts (“ADRs”) of GSK plc (NYSE: GSK) between February 5, 2020 and August 14, 2022, both dates inclusive (the “Class Period”), of the important April 7, 2025 lead plaintiff deadline. SO WHAT: If you purchased GSK ADRs during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangemen ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering GSK (GSK) , which belongs to the Zacks Medical - Biomedical and Genetics industry.When looking at the last two reports, this drug developer has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 10.40%, on average, in the last two quarters.For the last reported quarter, Glaxo came out with earnings of $0.59 per shar ...

Core Viewpoint - GSK plc is facing a class action securities lawsuit due to alleged securities fraud related to the withdrawal of Zantac from the market, impacting investors between February 5, 2020, and August 14, 2022 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that GSK misrepresented the reasons for removing Zantac from the market, stating it was based on available information and regulatory correspondence, while in reality, GSK was aware of the source of NDMA for nearly 40 years prior to the withdrawal [2]. - GSK assured investors that there was no evidence linking ranitidine therapy to cancer, which the lawsuit argues was materially false or misleading [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until April 7, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [4].